|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
2
|
|
gptkbp:awards
|
Best Biotech Company 2021
|
|
gptkbp:categories
|
Therapeutics
|
|
gptkbp:ceo
|
gptkb:John_Doe
|
|
gptkbp:clinical_trial
|
gptkb:200
Ongoing
Phase 1
Phase 3
|
|
gptkbp:collaborations
|
gptkb:Health_Insurance
|
|
gptkbp:community_engagement
|
Health Awareness Campaigns
|
|
gptkbp:employees
|
gptkb:500
|
|
gptkbp:established
|
gptkb:2000
|
|
gptkbp:financial_reports
|
Annual Report 2022
|
|
gptkbp:founded
|
gptkb:2000
|
|
gptkbp:founder
|
gptkb:Jane_Smith
|
|
gptkbp:headcount
|
gptkb:500
|
|
gptkbp:headquarters
|
gptkb:San_Diego,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
XYZ Biotech Inc.
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:invention
|
gptkb:20
|
|
gptkbp:investment
|
gptkb:Public
Research Grants
Venture Capital Group
|
|
gptkbp:investment_focus
|
gptkb:North_America
|
|
gptkbp:location
|
gptkb:California
|
|
gptkbp:market_cap
|
1 billion USD
|
|
gptkbp:market_launch
|
3 per year
|
|
gptkbp:member
|
gptkb:5
|
|
gptkbp:mission
|
Innovate in biotechnology
|
|
gptkbp:partnerships
|
gptkb:University_of_California
|
|
gptkbp:patent_applications
|
gptkb:15
|
|
gptkbp:products
|
Biopharmaceuticals
|
|
gptkbp:research_and_development
|
50 million USD
|
|
gptkbp:research_focus
|
gptkb:Gene_Therapy
|
|
gptkbp:research_institutes
|
Partnered with 3
|
|
gptkbp:revenue
|
100 million USD
15%
|
|
gptkbp:social_responsibility
|
Community Health Initiatives
|
|
gptkbp:stock_symbol
|
XYZB
|
|
gptkbp:subsidiaries
|
XYZ Diagnostics
|
|
gptkbp:sustainability_practices
|
Eco-friendly operations
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:training
|
Continuous Development Program
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:uses_technology
|
gptkb:CRISPR
|
|
gptkbp:vision
|
Transform healthcare through technology
|
|
gptkbp:website
|
www.xyzbiotech.com
|
|
gptkbp:bfsParent
|
gptkb:MTZ-1025
|
|
gptkbp:bfsLayer
|
7
|